

DETROIT OSTEOPATHIC HOSPITAL CORPORATION

21700 Greenfield Road •

Oak Park, Michigan 48237 • (313) 968-2800

November 21, 1986

RETURN RECEIPT REQUESTED Certified #P 050 326 878

"85 DEC 11 A10:50

Regional Licensing Section Radioisotopes Licensing Branch Division of Fuel Cycle and Material Safety U.S. Nuclear Regulatory Commission Region III 799 Roosevelt Road Glen Ellyn, Illinois 60137

Re: Byproduct Material License No. 21-04082-01

Gentlemen:

We wish to request that Nancy J. Andrews, D.O. be added to the above byproduct materials license. We request that Groups I, II, and III be approved, as well as, the use of iodine-131 for the treatment of hyperthyroidism and thyroid carcinoma. To facilitate this, we are enclosing a category 7C amendment fee of \$120.00.

Dr. Andrews was certified by the American Osteopathic Board of Nuclear Medicine on July 10, 1986. A copy of written rotification is enclosed, as is a copy of the preceptor statement signed by George J. Leach, D.O. concerning her experience with iodine-131 therapy procedures.


If you need additional information, please contact me.

Sincerely,

have Survey 20

Duane R. Darnell Executive Vice President, Chief Medical Officer

Enclosures



Log Ramitter Check Ma. Amount Fee Cetegory Type of Fee 2 Clote Check Rec'd Date Completed Der DEC 5 CONTROL NO. 82578 1986

212 EAST CHIO STREET, CHICAGO, ILLINOIS 60611 . AREA CODE 312 280-5800



American Osteopathic Association ADVISORY BOARD FOR OSTEOPATHIC SPECIALISTS

July 29, 1986

Nancy J. Andrews, D.O. 14049 Thirteen Mile Road Warren, Michigan 48093

Dear Dr. Andrews:

. . . 1.

This is to advise you that on July 10, 1986, the Board of Trustees of the American Osteopathic Association approved the recommendations of the American Osteopathic Board of Nuclear Medicine and the Advisory Board for Osteopathic Specialists to certify you as follows: . ,

Nuclear Medicine - Certificate No. 79

We wish to take this opportunity to congratulate you on this accomplishment.

A certificate is presently being prepared by the American Osteopathic Board of Nuclear Medicine. As soon as it has been lettered and signed by the appropriate officers, (approximately sixty days), it will be mailed to you.

Sincerely yours,

Jouglas Ward

Douglas Ward, Ph.D. Secretary

DW/prw

	FORM	SUPPLEMENT	B
(9-81)			

U. S. NUCLEAR REGULATORY COMMISSION

PRECEPTOR STATEMENT

Supplemen experience	nt B must be completed by the applicant phy , obtain a separate statement from each.	rsician's pr	eceptor. In	f more than one preceptor is necessary to document		
1. APPLICA	ANT PHYSICIAN'S NAME AND ADDRESS		KEY TO COLUMN C			
FULL NAME			PERSONAL PARTICIPATION SHOULD CONSIST OF: 1.Supervised examination of patients to determine the suitability for			
NANCY J. ANDREWS DO				radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.		
STREET ADDADS			2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.			
111	JTY IS MILL			e period of training to enable physician to manage radioactive		
WA	ARREN Mi 480	093	patients a treatmen	and follow patients through diagnosis and/or course of		
	2. CLINICAL TRAINING AND	EXPERI	ENCE OF	ABOVE NAMED PHYSICIAN		
ISOTOPE	CONDITIONS DIAGNOSED OR TREATED	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C		COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.)		
	DIAGNOSIS OF THYROID FUNCTION DETERMINATION OF BLOOD AND					
1-131	LIVER FUNCTION STUDIES					
or 1-125	or					
	KIDNEY FUNCTION STUDIES					
	IN VITRO STUDIES					
OTHER						
I-125	DETECTION OF THROMBOSIS					
1-131	THYROID IMAGING					
P-32	EYE TUMOR LOCALIZATION					
Se- 75	5 PANCREAS IMAGING					
Yb-169	69 CISTERNOGRAPHY					
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES					
OTHER						
Tc-99m	BRAIN IMAGING					
	CARDIAC IMAGING					
	THYROID IMAGING					
	SALIVARY GLAND IMAGING					
	BLOOD POOL IMAGING					
	PLACENTA LOCALIZATION					
	LIVER AND SPLEEN IMAGING					
	LUNG IMAGING					
	BONE IMAGING					
OTHER						

CONTROL NO. 82578

PRECEPTOR STATEMENT (Continued) 2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued) NUMBER OF CASES INVOLVING COMMENTS PERSONAL ISOTOPE CONDITIONS DIAGNOSED OR TREATED (Additional information or comments may be PARTICIPATION submitted in duplicate on separate sheets.) A В C D P-32 TREATMENT OF POLYCYTHEMIA VERA. (Soluble) LEUKEMIA, AND BONE METASTASES P-32 INTRACAVITARY TREATMENT (Colloidal) TREATMENT OF THYROID CARCINOMA 30 1-131 TREATMENT OF HYPERTHYROIDISM Au-198 INTRACAVITARY TREATMENT INTERSTITIAL TREATMENT or Cs-137 INTRACAVITARY TREATMENT 1-125 INTERSTITIAL TREATMENT • or 1r-192 Co-60 or TELETHERAPY TREATMENT Cs-137 Sr-90 TREATMENT OF EYE DISEASE RADIOPHARMACEUTICAL PREPARATION Mo-99/ Tc-99m GENERATOR Sn-113/ GENERATOR In-113m Tc-99m REAGENT KITS Other 3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING 7-7-80 - 6-30-82 8-1-83- Present 6. PRECEPTOR'S SIGNATURE 4 THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF A. NAME OF SUPERVISOR orge LRAC DO ol . NAME OF INSTITUTION (Please type or print) 7. PRECEPTOR'S NAME Bi-County et Port Ostropathic pitals 0 20 Leach Do C. MAILING ADDRESS NUR 48203 HIAHI PARK AND 10-22 MATEMALS LICENSE NUMBER(S) . NRC FORM 313M SUPPLEMENT B (9.81)

*

.